NCT06463457 - Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions

Prostate CancerAdvanced Prostate CancerHormone Sensitive Prostate Cancer

Interventions

DRUG

Darolutamide

Androgen receptor antagonist, tablet taken orally per protocol.

DRUG

Relugolix

Gonadotropin-releasing hormone (GnRH) receptor antagonist, tablet taken orally per protocol.

Trial Locations (3)

Beth Israel Deaconess Medical Center, Boston

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston